絞り込み

17703

広告

[Anti-heparin/platelet factor 4 antibodies and heparin-induced thrombocytopenia--review].

著者 Lei Q , Chen L
Zhongguo Shi Yan Xue Ye Xue Za Zhi.2008 Apr ; 16(2):457-60.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

Department of Anesthesiology, Fuwai Hospital, Institute of Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China.

スターを付ける スターを付ける     (83view , 0users)

Medical

Miscellaneous

Heparin-induced thrombocytopenia (HIT) is an antibody-mediated complication of heparin treatment that can lead to thrombosis and thromboembolism. HIT is mainly caused by immunoglobulin G (IgG) class among anti-heparin/platelet factor 4 antibodies that bind to epitopes on platelet factor 4 (PF4) released from activated platelets that developed when it forms complexes with heparin. Platelet aggregation and hypercoagulation status result from this process. Besides, the reactions between antibodies and vascular endothelial cells and monocytes are involved in HIT. Laboratory detection of anti-heparin/platelet factor 4 antibodies after heparin administration may help diagnose HIT early. Tests for detecting antibodies to the heparin/PF4 complex can be classified into functional platelet assays (which rely on the demonstration of platelet activation) and immunoassays (which detect the presence of an antibody without regard for its functional ability). But there is no simple and effective test available currently. In this article the anti-heparin/platelet factor 4 antibodies, pathogenesis of HIT, clinical laboratory assays and immunoassays are reviewed.
PMID: 18426686 [PubMed - indexed for MEDLINE]
印刷用ページを開く Endnote用テキストダウンロード